[Korea Biomedical Review] Why regulatory reform makes little progress in Korea

[Korea Biomedical Review] Why regulatory reform makes little progress in Korea

Why regulatory reform makes little progress in Korea WHY REGULATORY REFORM MAKES LITTLE PROGRESS IN KOREA "Lee Bo-hyoung, CEO of Macoll Consulting Group" Regulatory reform has been the No. 1 priority for every government in Korea. The Yoon Suk-yeol government made an ambitious promise to ease regulations to revitalize corporate activities. However, businesses still complain about the rare change in deregulation, and promises for regulatory reform are always repeated. So why has every administrat...

원문링크 : [Korea Biomedical Review] Why regulatory reform makes little progress in Korea

 등록된 다른 글

[Korea Biomedical Review] [Column] How should Korea improve national health insurance system?

[이데일리] "코로나19發 구조조정 현실화…집단적 노사 갈등 증가할 것" - 마콜컨설팅그룹 사장 이보형

[이투데이 인터뷰] 살충제 달걀 파동, 초기 대처 아쉬워… 사후 작업도 중요 - 마콜컨설팅그룹 사장 이보형

[연합뉴스]"금융위기 이후 '증시 활황 땐 집값 상승' 현상 뚜렷"

[한국경제 기고] 수소경제 첫걸음, 사회적 공감대도 넓혀야 - 마콜컨설팅그룹 사장 이보형

[Korea Biomedical Review] The distress of cancer patients and their families must also be healed

[매경춘추] 결심과 지속가능성 - 마콜컨설팅그룹 사장 이보형

[Korea Biomedical Review] Why regulatory reform makes little progress in Korea